GADD45B Facilitates Metastasis of Ovarian Cancer Through Epithelial-Mesenchymal Transition.
GADD45B
epithelial ovarian cancer
epithelial–mesenchymal transition
metastasis
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
09
2020
accepted:
11
12
2020
entrez:
20
1
2021
pubmed:
21
1
2021
medline:
21
1
2021
Statut:
epublish
Résumé
Growth arrest and DNA-damage-inducible 45 beta ( Bioinformatics analysis of The Cancer Genome Atlas (TCGA) and gene expression omnibus (GEO) cohorts was used to illustrate the relationship between Overexpression of GADD45B can promote the motility of ovarian cancer cells through EMT, is associated with EOC metastasis, and may be a new biomarker of metastasis and prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Growth arrest and DNA-damage-inducible 45 beta (
METHODS
METHODS
Bioinformatics analysis of The Cancer Genome Atlas (TCGA) and gene expression omnibus (GEO) cohorts was used to illustrate the relationship between
RESULTS
RESULTS
Overexpression of
CONCLUSION
CONCLUSIONS
GADD45B can promote the motility of ovarian cancer cells through EMT, is associated with EOC metastasis, and may be a new biomarker of metastasis and prognosis.
Identifiants
pubmed: 33469306
doi: 10.2147/OTT.S281450
pii: 281450
pmc: PMC7811469
doi:
Types de publication
Journal Article
Langues
eng
Pagination
255-269Informations de copyright
© 2021 Gong et al.
Déclaration de conflit d'intérêts
The authors declare no competing financial or non-financial interests.
Références
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Cell. 1998 Nov 13;95(4):521-30
pubmed: 9827804
J Biol Chem. 2003 Oct 31;278(44):43001-7
pubmed: 12933797
Int J Oncol. 2017 Oct;51(4):1199-1208
pubmed: 28902355
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
J Ovarian Res. 2017 Apr 13;10(1):27
pubmed: 28407786
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Res. 2018 Mar 1;78(5):1275-1292
pubmed: 29279355
Cancer Med. 2019 Oct;8(14):6426-6436
pubmed: 31490008
Endocrinology. 2011 Oct;152(10):3603-13
pubmed: 21810943
Crit Rev Oncog. 2011;16(1-2):129-40
pubmed: 22150313
Front Cell Dev Biol. 2020 Jul 08;8:605
pubmed: 32733895
Sci Rep. 2017 Nov 23;7(1):16188
pubmed: 29170526
J Neurochem. 2016 Oct;139(1):120-33
pubmed: 27385273
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Nat Cell Biol. 2004 Feb;6(2):146-53
pubmed: 14743220
Front Endocrinol (Lausanne). 2020 Apr 30;11:269
pubmed: 32425887
Oncogene. 2008 Feb 28;27(10):1429-38
pubmed: 17891184
Cancer Genomics Proteomics. 2016 11-12;13(6):407-423
pubmed: 27807064
Oncotarget. 2018 Sep 7;9(70):33360-33367
pubmed: 30279966
Cancer Lett. 2020 Apr 1;474:138-150
pubmed: 31987921
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Nature. 2001 Nov 15;414(6861):308-13
pubmed: 11713530
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Cancer Sci. 2012 Jul;103(7):1334-41
pubmed: 22497737
Cancer Cell. 2014 Oct 13;26(4):495-508
pubmed: 25314077
Cancers (Basel). 2019 May 14;11(5):
pubmed: 31091744
Int J Mol Sci. 2019 Jun 13;20(12):
pubmed: 31200510
Oncol Lett. 2018 Mar;15(3):3031-3041
pubmed: 29435034
Genes (Basel). 2018 Jul 19;9(7):
pubmed: 30029519
J Cell Biochem. 2020 Oct;121(10):4142-4153
pubmed: 32048761
Brain Behav Immun. 2015 May;46:60-9
pubmed: 25728234
Stem Cells Int. 2010 Mar 14;2010:782967
pubmed: 21048853
Cardiovasc Res. 2015 Nov 1;108(2):254-67
pubmed: 26370247
Front Oncol. 2020 Apr 07;10:499
pubmed: 32318352